BENDECTIN
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Jul 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 43m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Bendectin is an oral extended-release small molecule tablet approved in 1956 for an undisclosed indication. The specific mechanism of action and therapeutic class are not publicly detailed in available data. This legacy product represents a long-standing pharmaceutical asset with established market presence.
LOE Approaching
With LOE approaching and moderate competitive pressure (30/100), the brand team is likely in transition mode, focusing on lifecycle extension strategies or managed decline rather than growth expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Bendectin offers stability in a mature, established product environment, but limited growth trajectory. Career professionals should expect focus on retention, cost management, and market access rather than expansion and innovation.
Brand ManagerProduct Manager
Worked on BENDECTIN at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.